Glucagon vs PACAP-27
Head-to-head comparison of Glucagon (Glucagon) and PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) — benefits, dosing, side effects, research data, and where to buy.
| Property | Glucagon | PACAP-27 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Glucagon | Pituitary Adenylate Cyclase-Activating Polypeptide-27 |
| Molecular Weight | 3482.75 | 3158 Da |
| Half-Life | 5-10 min | minutes |
| Amino Acids | 29 | 27 |
| Typical Dose | 1 mg IM/SC for severe hypoglycemia or 3 mg intranasal | Research-only: 0.1-1 nmol/kg |
| Route | IM|SC|IN|IV | Intraperitoneal/Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 93 | 220 |
| Research Status | Approved | Pre-clinical |
Glucagon Benefits
- ✓rapid hypoglycemia reversal
- ✓raises plasma glucose
- ✓useful in emergency rescue
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Glucagon Dosing
1 mg IM/SC|3 mg intranasal
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Glucagon Side Effects
- ⚠nausea
- ⚠vomiting
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Research Overview
Glucagon
Clinical and emergency medicine use is well established for severe hypoglycemia, with newer stable formulations improving ease of administration.
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.